Elisabet I Nielsen

List of Publications by Year
in descending order

39 papers	1,557 citations	430874 18 h-index	315739 38 g-index
39 all docs	39 docs citations	39 times ranked	1570 citing authors

#	Article	IF	Citations
1	Population pharmacokinetics of cefotaxime in intensive care patients. European Journal of Clinical Pharmacology, 2022, 78, 251-258.	1.9	5
2	Continuous infusion of piperacillinâ€tazobactam significantly improves target attainment in children with cancer and fever. Cancer Reports, 2022, 5, e1585.	1.4	2
3	Imitation of Î²-lactam binding enables broad-spectrum metallo-Î²-lactamase inhibitors. Nature Chemistry, 2022, 14, 15-24.	13.6	39
4	Changes in critical inhaler technique errors in inhaled COPD treatment â€“ A one-year follow-up study in Sweden. Respiratory Medicine, 2022, 197, 106849.	2.9	3
5	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	7.3	17
6	Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. Npj Primary Care Respiratory Medicine, 2021, 31, 5.	2.6	7
7	From Therapeutic Drug Monitoring to Modelâ€informed Precision Dosing for Antibiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 928-941.	4.7	131
8	Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patientsâ€™ Use of Health Care. JAMA Network Open, 2021, 4, e216303.	5.9	22
9	Quantitation of seven sedative and analgesic drugs in whole blood from intensive care patients using liquid chromatography mass spectrometry. Toxicologie Analytique Et Clinique, 2021, 33, 327-327.	0.1	1
10	A novel mechanism-based pharmacokineticâ€“pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against Î²-lactamase-producing Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2020, 75, 400-408.	3.0	14
11	Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
12	Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. International Journal of Antimicrobial Agents, 2020, 55, 105941.	2.5	13
13	Intervention fidelity and process outcomes of medication reviews including postâ€discharge followâ€up in older hospitalized patients: Process evaluation of the MedBridge trial. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1021-1029.	1.5	6
14	Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106059.	2.5	18
15	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6. PLoS ONE, 2019, 14, e0211981.	2.5	15
16	Handling interoccasion variability in modelâ€based dose individualization using therapeutic drug monitoring data. British Journal of Clinical Pharmacology, 2019, 85, 1326-1336.	2.4	45
17	A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden . International Journal of COPD, 2019, Volume 14, 2451-2460.	2.3	12
18	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukinâ€6 and Câ€reactive protein by modelling. British Journal of Clinical Pharmacology, 2018, 84, 490-500.	2.4	12

#	Article	IF	Citations
19	Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli. International Journal of Antimicrobial Agents, 2018, 51, 399-406.	2.5	4
20	Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinsonâ€™s disease patients. European Journal of Clinical Pharmacology, 2018, 74, 1299-1307.	1.9	13
21	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 69-79.	1.8	33
22	Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. Journal of Antimicrobial Chemotherapy, 2017, 72, 3108-3116.	3.0	23
23	Medication Reviews Bridging Healthcare (MedBridge): Study protocol for a pragmatic cluster-randomised crossover trial. Contemporary Clinical Trials, 2017, 61, 126-132.	1.8	15
24	Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. Journal of Clinical Pharmacology, 2017, 57, 1573-1581.	2.0	20
25	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. Cancer Chemotherapy and Pharmacology, 2017, 80, 343-353.	2.3	20
26	Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics. Journal of Microbiological Methods, 2017, 132, 69-75.	1.6	11
27	Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. Pharmaceutical Research, 2016, 33, 1115-1125.	3.5	46
28	A pharmacokineticâ€“pharmacodynamic model characterizing the emergence of resistantEscherichia colisubpopulations during ertapenem exposure. Journal of Antimicrobial Chemotherapy, 2016, 71, 2521-2533.	3.0	12
29	Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. Antimicrobial Agents and Chemotherapy, 2016, 60, 4869-4877.	3.2	51
30	A pharmacokineticâ€“pharmacodynamic (PKPD) model based onin vitrotimeâ€“kill data predicts thein vivoPK/PD index of colistin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1881-1884.	3.0	26
31	Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1279-1290.	3.0	35
32	A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. Journal of Antimicrobial Chemotherapy, 2015, 70, 3051-3060.	3.0	35
33	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. Pharmaceutical Research, 2014, 31, 754-767.	3.5	67
34	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. Pharmacological Reviews, 2013, 65, 1053-1090.	16.0	248
35	Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. Antimicrobial Agents and Chemotherapy, 2012, 56, 179-188.	3.2	71
36	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. Antimicrobial Agents and Chemotherapy, 2011, 55, 4619-4630.	3.2	198

#	Article	IF	Citations
37	Predicting In Vitro Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1571-1579.	3.2	40
38	Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates. Clinical Pharmacokinetics, 2009, 48, 253-263.	3.5	71
39	Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments. Antimicrobial Agents and Chemotherapy, 2007, 51, 128-136.	3.2	143